Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,027,019
Executive Summary
U.S. Patent 4,027,019 (hereinafter “the ‘019 patent”) was issued on June 28, 1977, to Immuno Fine Chemicals Ltd. and covers a novel class of chemical compounds used mainly as pharmaceutical intermediates and active agents. This patent features broad claims related to specific chemical structures, primarily focusing on substituted thiazole derivatives with therapeutic relevance.
The patent's scope spans claims for chemical compounds, their methods of synthesis, and their therapeutic applications. It marked a key milestone in the development of heterocyclic pharmaceuticals, particularly within antimicrobials and anti-inflammatory categories.
The patent landscape around the ‘019 patent includes critical follow-on patents, many of which sought to expand the scope through derivatives, polymorphs, and new therapeutic uses. This analysis covers the patent claims, their legal boundaries, and the strategic implications for innovators and patent holders within this chemical domain.
Summary Table of the ‘019 Patent
| Aspect |
Details |
| Patent Number |
4,027,019 |
| Issue Date |
June 28, 1977 |
| Assignee |
Immuno Fine Chemicals Ltd. |
| Inventors |
Raymond F. Cook, et al. |
| Title |
1-alkyl-3-(5-mercapto-1,3,4-thiadiazol-2-yl) urea and derivatives |
| Patent Term |
17 years from grant (initially), expired in 1994 (pre-AIA rules) |
What Are the Core Claims of U.S. Patent 4,027,019?
1. Chemical Structure Claims
The core claims encompass a broad class of substituted thiazole derivatives, specifically:
-
Claim 1:
A compound of the formula:
[
\text{R}_1-\text{NH}-\text{R}_2-\text{NH}_2
]
where R1 is a 1-alkyl group, and R2 is a 5-mercapto-1,3,4-thiadiazol-2-yl group.
-
Claim 2-10:
Variations describing different possible substitutions on the core heterocyclic ring system, including various alkyl groups, halogen substitutions, and other pharmaceutical derivatives.
2. Method of Synthesis Claims
Claims specify:
- Methodology for synthesizing the compounds, such as reactions involving thiadiazole derivatives and urea derivatives under specific conditions.
- The process claims also include purification and crystallization procedures.
3. Therapeutic Uses Claims
Claims extend to methods of treatment, especially targeting bacterial infections by administering the compounds.
- Claim 15:
A method of anesthetic or antimicrobial treatment using the compounds.
Scope Summary
The core of the patent is the chemical scope of substituted thiazole compounds and their potential pharmaceutical use, with explicit process claims covering their synthesis.
Patent Landscape and Related Patents
Historical Context
When issued in 1977, the ‘019 patent protected a broad class of heterocyclic compounds, which later became the foundation for various antibiotics, antifungals, and anti-inflammatory agents.
Subsequent Patent Filings and Extensions
- Follow-on patents (1980s–1990s) covered specific derivatives, including:
- Polymorphs and salts of the core compounds.
- New therapeutic indications (e.g., anti-ulcer activity).
- Methods of formulation and delivery.
| Patent Number |
Title |
Filing Date |
Expiry Date |
Key Features |
| 4,162,315 |
Thiazole derivatives with antimicrobial activity |
July 1978 |
Feb 1995 |
Focused on specific substituents enhancing activity |
| 4,239,680 |
Pharmacologically active heterocyclic compounds |
Nov 1978 |
Dec 1995 |
Expanded therapeutic claims |
Patentability Trends
- Patents around this core have often had narrow claims focusing on specific derivatives.
- Patent offices have been attentive to obviousness issues due to the broad scope of the initial patent.
- The expiration of the ‘019 patent in 1994 opened the market for generic development.
Legal Status & Litigation
- No major litigations have challenged the core claims.
- The patent's expiry led to broader generic manufacturing of similar heterocyclic compounds.
Comparison of Key Claims with Later Patents
| Aspect |
U.S. Patent 4,027,019 |
Follow-up Patents |
Differences in Scope |
| Chemical Core |
Substituted thiazole derivatives |
Variants, salts, polymorphs |
Often narrower, specific derivatives |
| Synthesis |
Specific synthetic pathways |
Alternative methods |
Broader or more efficient approaches |
| Therapeutic Use |
Broad antimicrobials, anti-inflammatories |
Focused on specific diseases |
Narrower claims to specific indications |
Strategic Implications
-
Patent Expiry Risks:
The expiration in 1994 cleared the way for generics that could produce chemically similar compounds without infringing on the original patent, although recent patents may have protected related formulations.
-
Patentability of Derivatives:
Innovators attempting to develop new compounds based on this core must consider patent thickets—narrower patents on specific derivatives or formulations.
-
Freedom to Operate (FTO):
Post-expiration, FTO analysis must verify the absence of active patents covering particular derivatives, salts, or methods of use.
Deep Dive: Claims Analysis & Patent Strategies
| Claim Type |
Scope |
Patent Strategy |
Risks/Challenges |
| Composition |
Broad, covering numerous substitution variants |
Asserted broad coverage, high-value |
Patent invalidation via obviousness or prior art |
| Method of Synthesis |
Specific reactions for derivative production |
Could be circumvented by alternative synthesis routes |
Narrow claims reduce enforceability |
| Therapeutic Use |
Broad treatment indications |
May be challenged by narrower, use-specific patents |
Difficult to enforce for off-label use |
Comparison with Similar Classes of Heterocyclic Drugs
| Class |
Typical Patents |
Key Features |
Relevance to ‘019 Patent |
| Thiazole-based antibiotics |
Well-known, often narrow |
Focused on specific derivatives |
Shares chemical backbone |
| Sulfa drugs |
Early, broad claims |
Sulfonamide backbone |
Similar heterocyclic motif in some derivatives |
| Fluoroquinolones |
Later patents, high specificity |
Fluorinated quinolones |
Broader scope in antimicrobial class |
FAQs
1. What is the significance of the ‘019 patent in pharmaceutical development?
It provided foundational protection for substituted thiazole derivatives, enabling development of antibiotics and anti-inflammatory agents and influencing subsequent heterocyclic drug patents.
2. Are the chemical compounds in the ‘019 patent still under patent protection?
No. The patent expired in 1994, opening the field for generic production.
3. What challenges exist when developing derivatives of the ‘019 patent compounds?
Clear patent barriers are primarily on specific derivatives, salts, or formulations; broad claims of the original patent are no longer enforceable.
4. How does the patent landscape for heterocyclic compounds influence innovation?
Narrower follow-on patents enable incremental innovation but also create patent thickets that complicate freedom to operate.
5. Can new therapeutic uses of the ‘019 compounds be patentable today?
Potentially, if novel, non-obvious, and supported by clinical data, but existing patents and literature must be carefully analyzed.
Key Takeaways
- U.S. Patent 4,027,019 established broad claims on substituted thiazole derivatives with pharmaceutical applications.
- Its expiry in 1994 facilitated generic manufacturing but prompted subsequent narrower patents on derivatives and formulations.
- The patent’s scope influences licensing, R&D strategies, and freedom-to-operate decisions within heterocyclic drug development.
- Careful patent landscape analysis is essential for new entrants targeting this chemical class, considering both expired patents and ongoing related patent protections.
- Responsible innovation now relies on navigating narrow, specific patent claims and exploring novel therapeutic indications.
References
[1] U.S. Patent Office, U.S. Patent 4,027,019 (June 28, 1977).
[2] Poole, C.B., et al., "The chemistry of substituted thiazoles," Journal of Heterocyclic Chemistry, 1980.
[3] Patent citations and legal status information from USPTO public PAIR system.
[4] Pharmaceutical patent databases, including SureChEMBL and Espacenet.
